Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

US Patent 10308717 · Granted Jun 4, 2019

Estimated economic value: $17,225,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-TCR antibody molecules and uses thereof2025
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosi2025
Targeted t cells with cytotoxicity toward immunosuppressive cells2025
Modified T cells and methods of their use2025
Multispecific antibody molecules comprising lambda and kappa light chains2025
Compositions and methods for immune tolerance2025
Switch costimulatory receptors2025
Chimeric antigen receptors and uses thereof2025
Antibody molecules that bind to NKP30 and uses thereof2025
Chimeric antigen receptor T cells targeting the tumor microenvironment2025
Multifunctional molecules that bind to T cell related cancer cells and uses ther2025
Compositions and methods for generating a persisting population of T cells usefu2025